Klotho Therapeutics, Inc.

Klotho Therapeutics focuses on developing therapeutic solutions utilizing the Human Klotho Protein to address aging and age-related diseases, targeting health challenges such as cognitive decline and kidney failure. Founded in 2016 and headquartered in San Diego, US, Klotho Therapeutics, Inc. specializes in the synthetic replication of the Klotho protein, which is crucial for longevity. The company raised USD 10 mn in Series A funding in November 2017, led by Thynk Capital.

Klotho Therapeutics operates independently and has not undergone significant pivots since its inception. Klotho Therapeutics (KTI) specializes in the development of a patented Human Klotho Protein aimed at addressing key challenges associated with aging and age-related diseases. The core product involves the synthetic replication of the Klotho protein, which is naturally produced in the kidneys and believed to play a significant role in longevity and overall health. This protein is designed to target various health issues, including cognitive decline, kidney failure, diabetes, and cancer, providing potential therapeutic benefits to patients suffering from these conditions.

KTI’s offerings primarily cater to healthcare providers, research institutions, and pharmaceutical companies focusing on aging-related therapies and biomarkers. The geographical markets for these products include North America, Europe, and select regions in Asia, where there is a growing emphasis on anti-aging treatments and healthcare innovations. Klotho Therapeutics generates revenue through partnerships, collaborations, and potential licensing agreements with pharmaceutical companies and research organizations. The company structures its transactions around the development and commercialization of its Klotho protein, targeting both B2B relations with healthcare providers and direct collaborations with research institutions.

These transactions are typically structured to facilitate clinical trials, validation of safety and efficacy, and potential future product commercialization. While specific pricing plans for the flagship Klotho protein are not disclosed, the revenue model may involve milestone payments, research funding, or royalties from successful product development and market launch. This multi-faceted approach enables KTI to capitalize on advances in biotechnology and the growing demand for solutions addressing age-related health challenges. Klotho Therapeutics plans to expand its research and development initiatives with the recently raised USD 10 mn in Series A funding from Thynk Capital.

This funding will support the ongoing development of new products based on the Klotho protein. The company aims to broaden its market reach into Europe and Asia by the end of 2024, focusing on partnerships with healthcare providers and research institutions to advance its clinical trials and facilitate the commercialization of its therapeutic solutions.